Citi lowered the firm’s price target on ArriVent Biopharma (AVBP) to $31 from $33 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma Reports Q3 2025 Financial Results
- ArriVent BioPharma’s Promising Trial Results and Strategic Developments Drive Buy Rating
- ArriVent Biopharma reports Q3 EPS (83c), consensus (78c)
- ArriVent Biopharma price target raised to $47 from $32 at Clear Street
- ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment